AstraZeneca ponders a China pharma spinoff to protect itself from geopolitical fallout — FT

John Carroll

Editor & Founder

As senior government officials in the US warily look to stabilize rocky relations with China, one global pharma giant has been considering a corporate restructuring …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca ponders a China pharma spinoff to protect itself from geopolitical fallout — FT

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer’s prostate cancer data leak shows promising results in early-stage study

Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos

What will pharma's share buyback shopping spree mean for M&A?

Vertex operations chief Stuart Arbuckle to retire

Updated: Judge halts NIH cuts nationwide after groups, 22 states sue

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

As­traZeneca pon­ders a Chi­na phar­ma spin­off to pro­tect it­self from geopo­lit­i­cal fall­out — FT

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

AstraZeneca ponders a China pharma spinoff to protect itself from geopolitical fallout — FT